Cindy McReynolds’s research focuses on investigating the metabolism and distribution of small molecule inhibitors, and identifying target engagement and biomarkers to improve outcomes in clinical trials. Prior to completing her PhD, Dr. McReynolds worked as program manager for multiple clinical and research programs in academia and industry, where she explored the role of nutrition and the environment on disease in both human and animal health. She returned to school to study pharmacology and toxicology with a goal of bringing safe and effective medicines to people with unmet medical needs. She received her PhD in 2021 at the University of California, Davis, where she worked in the laboratory of Dr. Bruce Hammock studying the roles of bioactive lipids in health and disease. After completing her degree, she was appointed CEO of EicOsis Human Health, a company founded with Dr. Hammock to develop safe and effective treatments for neuroinflammatory diseases.